Featured News

LYMPHOMA

LymphExpress Dx™ v.1.0 is a gene expression-based microarray diagnostic test for the most common subtypes of lymphoma, together representing approximately 90% of all Non-Hodgkin B-cell and Hodgkin lymphomas. In a recent study, LymphExpress Dx™ v.1.0 achieved an overall accuracy rate of over 90%. MBI is currently developing a second generation prototype, LymphExpress Dx™ v.2.0, to diagnose additional subtypes of lymphoma, in total representing approximately 98% of all Non-Hodgkin B-cell and Hodgkin lymphomas.

MBI and Duke University have been collaborating since February 2007, and recently established the Translational Working Group in Hematologic Malignancies (Working Group), to develop LymphExpress Dx™. MBI and Duke are currently finalizing initial membership in the Working Group, which is expected to include a world-class international consortium of universities and principal investigators who are thought leaders in lymphoma research and treatment.

The lead principle investigator of the Working Group is Duke’s Sandeep S. Davé, M.D. Dr. Davé is the lead author of two of the most cited papers in the field of molecular profiling of lymphomas, both of which were published in the New England Journal of Medicine: “Molecular diagnosis of Burkitt's lymphoma” (Davé et al. 2006 NEJM 354: 2431) and “Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells” (Davé et al. 2004 NEJM 351: 2159).

About Lymphoma

Lymphoma is the fifth most common cancer in the United States and is a general term for a group of cancers that originate in the lymphatic system and is comprised of more than 42 disease subtypes. Lymphoma is divided into two major categories: Non-Hodgkin lymphoma, representing 88% of all lymphomas, and Hodgkin lymphoma, representing approximately 12% of all lymphomas. 85% of Non-Hodgkin lymphomas arise from B-cell malignancies and represent the most lethal lymphoma subtypes.

In the United States, lymphoma afflicts approximately 74,000, and kills approximately 20,500, people each year. Currently, approximately 40% of persons diagnosed with B-cell Non-Hodgkin lymphoma will die within five years.

Diagnosis and treatment of patients with lymphoma costs approximately $4.6 billion per year in the United States alone, with an average per patient expenditure of $21,500 in the first year after diagnosis.

E-MAIL ALERTS

Subscribe to our e-mail news alerts

Quick Facts

Download our facts sheet